PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Florbetaben→

Florbetaben PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
902143-01-5
Molecular formula
C21H26[18F]NO3
Molecular weight
358.4 g/mol
Drug class
18F-labelled amyloid beta PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds fibrillar amyloid beta plaques in the brain. Positron emission tomography detects the radiotracer distribution to estimate the presence or absence of amyloid pathology; it is not a treatment for Alzheimer disease.
Indications / reported uses
  • PET imaging of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment being evaluated for Alzheimer disease or other causes of cognitive decline; scan results must be interpreted with clinical assessment

Sources: US DailyMed — NEURACEQ (florbetaben F18) · EMA EPAR — Neuraceq · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Florbetaben PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Florbetaben Permitted Daily Exposure (PDE) report (the Florbetaben PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Florbetaben Occupational Exposure Limit (OEL) report (the Florbetaben OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.